Michael Powell, Director at Orexigen Therapeutics, Inc. (OREX), sold 700,000 shares at $6.29 ($4.3M) on 2010-03-17, disclosed to the SEC on 2010-03-19.
Open-market sale of $4.3M OREX by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.29 | 1,702 | $11K | 0.2% |
| 2 | $6.29 | 24,867 | $156K | 3.6% |
| 3 | $6.29 | 125,431 | $789K | 18.4% |
| 4 | $6.15 | 3,786 | $23K | 0.5% |
| 5 | $6.15 | 55,297 | $340K | 7.9% |
| 6 | $6.15 | 278,917 |
| $1.7M |
| 39.9% |
| 7 | $6.00 | 2,352 | $14K | 0.3% |
| 8 | $6.00 | 34,356 | $206K | 4.8% |
| 9 | $6.00 | 173,292 | $1.0M | 24.2% |
| Total | $6.14 avg | 700,000 | $4.3M | 100% |
| Filing → |
| OCRX | SELL | 2016-12-30 | $15K | — | Filing → |
| MIRN | BUY | 2015-10-06 | $6.0M | — | Filing → |
| AERI | SELL | 2014-07-11 | $24.2M | — | Filing → |